Background: To evaluate the difference at different steps of follow-up of the postoperative quality of life (QoL) in patients who had undergone radical cystectomy and ileal orthotopic neobladder derivation. Patients and Methods: A multicentric, cross-qualitative study was performed in 5 Italian centers of reference for the treatment of bladder cancer. One hundred seventy one patients who underwent radical cystectomy and creation of ileal orthotopic neobladder according to ‘Vescica Ileale Padovana' between 2006 and 2011 have been analyzed. The validated and dedicated questionnaires EORTC QLQ-C30, IOB-PRO and EORTC QLQ-BLM30 were used. Results: All data gathered were then processed, specifically means ± SD were included for comparison during 4 periods of follow-up (quartile): the first ranging from 1 to 18 months; the second ranging from 19 to 36 months; the third from 37 to 72 months and the fourth >72 months. Cancer-specific and health-related factors were analyzed separately, and the change was determined during follow-up. Conclusions: The global QoL, highlighted by validated cancer-specific and health-related questionnaires, is certainly on a satisfactory level. Thus, the education of the patient, the exploration of the pros and cons of an orthotopic neobladder and the active participation in treatment decision seem to be the keys to better improve the post-operative QoL during the follow-up period.

Keywords:
Quality of life, Ileal neobladder, Bladder cancer
1.
EAU Guidelines, 2013.
2.
Stenzl A, Sherif H, Kuczyk M, et al: Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. Int Braz J Urol 2010;36:537-547.
3.
Gerharz EW, Månsson A, Hunt S, et al: Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol 2005;174:1729-1736.
4.
Bjerre BD, Johansen C, Steven K: Health-related quality of life after cystectomy: bladder substitution compared with ileal conduit diversion. A questionnaire survey. Br J Urol 1995;75:200-205.
5.
Hedgepeth RC, Gilbert SM, He C, et al: Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. Urology 2010;76:671-675.
6.
Kitamura H, Miyao N, Yanase M, et al: Quality of life in patients having an ileal conduit, continent reservoir or orthotopic neobladder after cystectomy for bladder carcinoma. Int J Urol 1999;6:393-399.
7.
Dellis AE, Papatsoris AG, Skolarikos AA, et al: Modified S-ileal neobladder for continent urinary diversion: functional and urodynamic results after 20 years of follow-up. Urol Int 2014;93:43-48.
8.
Selli C, Giannarini G, De Maria M, Pistolesi D, Thalmann GN: Radical cystectomy and ileal orthotopic bladder substitution after radical retropubic prostatectomy: functional and oncological results. Urol Int 2014;93:237-240.
9.
Yoneda T, Adachi H, Urakami S, et al: Health related quality of life after orthotopic neobladder construction and its comparison with normative values in the Japanese population. J Urol 2005;174:1944-1947.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.